CHAPTER 01 / 10
Executive thesis
Durable accountable-care value is created when an organization can price risk, underwrite interventions, orchestrate access, bend medical cost persistently, convert savings to cash, and earn an attractive risk-adjusted return on required capital. This requires an integrated operating and financial model that aligns clinical outcomes, member experience, and unit economics at scale. Organizations that combine data-driven risk selection, disciplined capital allocation, and executable care delivery can transform access into a source of financial resilience and long-term enterprise value in New York’s evolving healthcare market over 2026–2030.
How accountable access becomes enterprise value
- Population
Defined lives, needs and risk
- Revenue yield
Risk-adjusted payment and incentives
- Access
Timely, equitable, coordinated
- Intervention
Evidence-based care and support
- Medical cost
Lower trend, better outcomes
- Settlement
Reconcile performance and shared savings
- Cash flow
Convert savings to cash
- Capital
Deploy and reinvest efficiently
- Enterprise value
Sustainable growth and resilience
| Value-system stage | Operating meaning |
|---|---|
| Population | Defined lives, needs and risk |
| Revenue yield | Risk-adjusted payment and incentives |
| Access | Timely, equitable, coordinated |
| Intervention | Evidence-based care and support |
| Medical cost | Lower trend, better outcomes |
| Settlement | Reconcile performance and shared savings |
| Cash flow | Convert savings to cash |
| Capital | Deploy and reinvest efficiently |
| Enterprise value | Sustainable growth and resilience |
| Dimension | Sequence |
|---|---|
| Risk | Identify · Price · Manage · Share |
| Data | Integrate · Analyze · Inform · Improve |
| Time | Plan · Execute · Measure · Scale |
Four imperatives for CFOs
01 / Revenue quality matters
Sustainable value comes from risk-adjusted, recurring revenue with measurable outcomes, not top-line growth alone.
02 / Medical cost is a portfolio
Costs vary by population, condition, and intervention. Treat medical cost as a portfolio to actively manage risk, mix and trend.
03 / Cash is not earnings
Accounting profit differs from cash generation. Convert medical savings into real cash through disciplined settlement, working capital, and reinvestment choices.
04 / Capital efficiency determines value
The ability to generate an attractive, risk-adjusted return on required capital ultimately drives enterprise value.
Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 02 / 10
Executive summary & market inflection
Accountable care is entering a new phase in New York, driven by the convergence of federal and state policy, expanded access models, and data infrastructure. Between 2026 and 2030, the economics of accountable care will shift from episodic revenue and fee-for-service contracting to outcome-based, multi-year value creation through access, intervention, and population health. Organizations that align capital, clinical, and operating models to this new reality can convert medical-cost volatility into predictable cash flow, stronger margins, and long-term enterprise value.
Five structural shifts changing accountable-care economics
01 / Accountability is deepening in MSSP and Medicare accountable care.
Higher performance standards, greater downside risk, and more sophisticated benchmarking are accelerating the shift from upside-only models to true two-sided risk requiring more disciplined care management and financial execution.
02 / LEAD creates a long-duration 2027–2036 benchmark and risk horizon.
The CMS LEAD model establishes a 10-year performance window, providing unprecedented stability for planning, capital deployment, and population health investment.
03 / ACCESS creates an outcome-paid chronic-care supply layer.
The ACCESS model builds a dedicated, outcome-based infrastructure for chronic care, expanding the supply of services and enabling earlier intervention, better health outcomes, and lower total cost of care.
04 / AHEAD and hospital global budgets reprice hospital incentives.
New York’s AHEAD model and global budgets align hospital economics with population health, reducing incentives for avoidable utilization and creating stronger incentives for care coordination and community health investment.
05 / Interoperability and New York social-care infrastructure reduce data and access friction.
CMS-0057-F API requirements and New York’s social-care infrastructure (NYHER, HIE, community networks) improve data liquidity, close care gaps, and enable more coordinated, equitable access to services across the enterprise and community.
| Year | Milestone |
|---|---|
| 2026 | ACCESS launches; NY AHEAD / NYHER infrastructure advances. |
| 2027 | LEAD begins; CMS-0057-F API requirements begin broadly. |
| 2028 | ACCESS expenditures begin entering relevant ACO economics. |
| 2030 | Accountable access matures into an enterprise operating model. |
| Today | 2026–2030 |
|---|---|
| Volume and utilization | Risk pricing and population accountability |
| Contracting and rate negotiation | Intervention underwriting and outcome-based payment |
| Fragmented point solutions | Access orchestration across medical and social care |
| Siloed data | Data liquidity and interoperability |
| Transactional revenue | Retained value and enterprise growth |
The strategic question is no longer how large the network can become, but who can orchestrate access while preserving longitudinal accountability and retained enterprise value.
Source cited in the original: CMS, New York State DOH, public filings, and peer-reviewed literature (2025–2026).
CHAPTER 03 / 10
Revenue quality, risk adjustment & Medicare Advantage yield
Understanding the components of MA revenue yield is essential capital allocation, and long-term value creation.
Executive summary
Medicare Advantage revenue yield is shaped by more than the annual CMS rate announcement. For 2027, CMS finalized an average expected payment increase of approximately 2.48% before coding trend. 2026 completed the transition to the 2024 CMS-HCC risk adjustment model, creating a more stable baseline for future years. Going forward, yield will reflect a combination of base rate growth, risk-model normalization, changes in diagnosis sources, quality performance, and other policy and mix factors. For health-plan CFOs, decomposing these components is critical to separate true earnings power from temporary or non-recurring effects.
Revenue yield has several moving parts
The source separates the headline growth assumption from risk, diagnosis, quality, and mix effects.
| Component | Illustrated value |
|---|---|
| 2026 average payment (index) | 100.0 |
| Base effective growth rate (CMS rate) | 2.48% |
| Risk-model revision / normalization | (0.80%) |
| Diagnosis-source changes | 0.50% |
| Quality / Stars effects | 0.70% |
| Other mix / policy factors | (0.20%) |
| 2027 expected average payment (index) | 102.7 |
Key points
- CMS finalized an average expected payment increase of approximately 2.48% for 2027 before coding trend.
- 2026 completed the transition to the 2024 CMS-HCC risk adjustment model, creating a more stable baseline.
- Revenue yield reflects multiple components beyond the base rate, including risk model changes, diagnosis sources, quality performance, and organizational mix.
| Layer | Components |
|---|---|
| 1 / Base premium / capitation | County benchmark, plan bid, and statutory factors |
| 2 / Risk adjustment | CMS-HCC risk scores based on member clinical profile |
| 3 / Quality economics | Stars scores, quality bonuses, and withholds |
| 4 / Rebates / benefits | Part D rebates, supplemental benefit payments, and other offsets |
| 5 / Settlement / model-specific payments | Risk corridors, transition, and other model-specific payments |
MLR boundary condition
Medicare Advantage plans must maintain a minimum Medical Loss Ratio (MLR) of 85% (benefits plus quality improvement expenses). This means that lower medical cost does not translate one-for-one into margin, as a significant portion of any savings must be reinvested in member benefits or quality improvement activities. CFOs must evaluate revenue yield and medical cost performance together, recognizing the MLR constraint when assessing earnings power.
Risk adjustment is a revenue-accuracy function, rather than a coding-growth exercise. Its purpose is to ensure payments reflect member health status, not to drive unlimited revenue growth.
Revenue growth must be decomposed into price, risk, quality, mix, policy, and membership before it is treated as true earnings power.
Source cited in the original: CMS Final Rate Announcement (CY 2027), CMS-HCC Model Information, Medicare Advantage Regulations, industry analysis, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 04 / 10
Medical cost as a portfolio & the CFO value bridge
Understanding the flow from risk-adjusted revenue to economic profit — and where CFOs can create value through disciplined medical cost management, investment, and capital allocation.
From $10B in revenue to $0.7B after the capital charge
The illustrated medical margin is $3.0B; care investment, operations, settlement, and capital charges reduce the remaining value to $0.7B.
$10.0B in revenue becomes $3.0B in medical margin.
The first deduction is the $7.0B incurred medical cost. Medical margin is a subtotal of the same bridge, not new revenue and not cash.
$10.0B − $7.0B = $3.0BWhich medical-cost categories respond to intervention, and which reflect severity or volatility?
Inspect the related evidenceThe care system must still be funded and reconciled.
The illustration deducts $0.8B for care and provider investment, $0.6B for operations, and $0.4B for settlement and quality economics.
$3.0B − $0.8B − $0.6B − $0.4B = $1.2B before capital chargeWhat is retained after the cost of delivery and the settlement terms?
Inspect the related evidenceThe capital charge takes the remaining value to $0.7B.
The source illustration applies a $0.5B capital charge to the $1.2B calculated remainder.
$1.2B − $0.5B = $0.7BDoes the retained return justify required capital and downside exposure?
Inspect the related evidence| Component | Billions | Description |
|---|---|---|
| Risk-adjusted revenue | $10.0B | Premium, capitation and other revenue net of risk |
| Incurred medical cost | ($7.0B) | Total cost of care |
| Medical margin | $3.0B | Revenue less medical cost |
| Care / provider investment | ($0.8B) | Care management, provider enablement, value-based programs |
| SG&A / operations | ($0.6B) | People, technology, administration and member experience |
| Settlement & quality economics | ($0.4B) | Risk settlement, quality incentives and shared savings |
| Capital charge | ($0.5B) | Cost of capital for growth and balance sheet risk |
| Economic profit / free cash flow | $0.7B | Cash available for reinvestment, debt, and returns to shareholders |
Disciplined medical cost management translates care performance into economic value.
Medical spend is a portfolio of distinct cost pressures
Inpatient (22%) and outpatient (18%) are the largest categories in the published illustration.
Source share · zero to 25%
| Cost category | Share | Amount | Drivers |
|---|---|---|---|
| Inpatient | 22% | $1.54B | High severity, length of stay |
| Emergency department | 6% | $0.42B | Avoidable use, site of care |
| Outpatient | 18% | $1.26B | Site and price variation |
| Professional | 12% | $0.84B | Practice pattern, utilization |
| Specialty | 14% | $0.98B | High-cost therapies, prior authorization |
| Pharmacy | 10% | $0.70B | Brand mix, rebates, adherence |
| Post-acute | 6% | $0.42B | SNF, IRF, home health, readmissions |
| Behavioral health | 6% | $0.42B | Access, integration, continuity |
| Home / community | 4% | $0.28B | In-home care, CSLT, social needs |
| External intervention spend | 3% | $0.21B | Care management, SDOH, vendor programs |
| Large-case volatility | 2% | $0.14B | Catastrophic claims, stop-loss |
Source-table note. The original labels total incurred medical cost at $7.0B. Its listed categories sum to 103% and $7.21B. The figures are reproduced as published; they do not form a reconciled allocation. The bridge also uses the combined label “Economic profit / free cash flow”; the article distinguishes these measures below.
Intervention ROI formula
Avoided expected medical cost + Quality / revenue benefit + Persistence value − Program cost − Incremental utilization − Operating cost = Net medical-cost value
Net medical-cost value × Retention rate = Enterprise value captured
Key insight
Cash receipts, accounting margin, shared savings, and free cash flow are distinct — and each tells a different story.
CFOs create lasting value when they understand the differences, connect them through a consistent model, and manage the trade-offs across care, capital, and growth.
Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 05 / 10
LEAD 2027–2036: long-duration benchmark economics
From Prospective Payment to Enterprise Value. A 10-Year Model for Sustainable, Accountable Growth.
The LEAD model establishes a 10-year, prospective benchmark that aligns payment, quality, and risk around a long-term horizon. By moving beyond annual settlements, LEAD creates predictable cash flow, enables strategic capital allocation, and supports sustained enterprise value in New York’s evolving healthcare market.
| Feature | Professional risk — aligned, scalable | Global risk — full accountability |
|---|---|---|
| Share of total savings | Up to ~60% of total savings | Up to 100% of total savings |
| Share of total losses | Up to ~50% of total losses | Up to 100% of total losses |
| Risk exposure | Primarily professional services (e.g., primary care and select specialties) | Broader, all-payer and all-service exposure (including inpatient, post-acute, and pharmacy) |
| Capitation options | Primary care capitation and non-primary care capitation available | Primary care capitation, total care capitation, non-primary care capitation, and advanced payment options |
| Typical fit | Organizations building experience, managing defined risk | Experienced, well-capitalized organizations seeking full accountability |
| Key consideration | Moderate risk with meaningful upside | Greater opportunity with higher risk and capital requirements |
Key model elements
- 10-year model horizon: begins in 2027, spanning 2027–2036.
- Quality withhold: 3%, held for quality performance.
- Benchmark discount / hurdle: aligned with CMS methodology and market dynamics.
- Administrative add-on: 1.5%, for eligible higher-spending ACOs.
- Capitation & advanced payments: primary care capitation; total care capitation; non-primary care capitation; advanced payment options.
- Risk mitigation: risk corridors; stop-loss protection; financial guarantees.
| Horizon | Value mechanism |
|---|---|
| 2025 | Historical performance establishes baseline |
| 2027 | Prospective benchmark begins |
| 2027–2036 | Performance, learning, and reinvestment compound value |
| Beyond 2036 | Stronger market position, brand equity, and enterprise value |
Short-term settlements → Long-duration enterprise asset.
CFO interpretation
Prospective payment changes liquidity, not necessarily margin.
The real question for CFOs is the incremental expected return versus the incremental tail risk and required capital. LEAD should be evaluated as a portfolio decision — balancing cash flow stability, risk exposure, and strategic optionality over the full 10-year horizon.
Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 06 / 10
ACCESS: outcome-priced chronic care as an underwriting problem
A Financial Framework to Turn Care Delivery Into Measurable, Investable Value.
ACCESS (Accountable Care, Coordinated, Evidence-based, Scalable Supports) reframes chronic-care delivery as an underwriting problem. By pricing defined, evidence-based interventions and linking payment to outcomes, organizations can convert chronic-care capacity into a predictable, portfolio-level investment with measurable medical cost impact. ACCESS creates a standard unit of intervention, a clear payment architecture, and a defined learning period so that expenditures enter ACO economics once real-world performance has been observed and validated.
Illustrative annual ACCESS allowances vary by intervention
The article illustrates $420 for CKM, $360 for early CKM, and $180 each for musculoskeletal and behavioral health.
Approximate first-year USD per beneficiary annually
These article illustrations are not independently verified current CMS rates, realized revenue, or margin.
| Program / intervention | Approx. first-year allowed amount (per beneficiary annually) | Focus |
|---|---|---|
| Early CKM | $360 | Rising risk, early engagement |
| CKM | $420 | Complex chronic conditions |
| Musculoskeletal | $180 | MSK pain, function, return to work |
| Behavioral health | $180 | Mental health, substance use |
PCP co-management economics are roughly $30 per qualifying coordination service, up to three times annually; plus a one-time onboarding payment where applicable.
The ACCESS learning window
2026–2027 / Portfolio-learning period
- Deploy interventions
- Collect real-world evidence
- Measure clinical and financial outcomes
- Refine targeting, operations, and unit economics
2028 onward / Enter ACO economics
- ACCESS expenditures begin entering relevant ACO economics
- Apply validated outcomes to contracting, pricing, and capital allocation
- Scale high-performing interventions
- Drive sustained medical cost reduction and enterprise value
Intervention underwriting
An intervention is financially attractive when the risk-adjusted, persistent medical cost savings exceed the intervention cost.
Expected return per beneficiary = [Avoided longitudinal medical cost (per beneficiary) × P(outcome) × Persistence × Enterprise retention rate] − Intervention cost (per beneficiary)
| Variable | Meaning |
|---|---|
| Avoided longitudinal medical cost | Incremental medical spend reduction attributable to the intervention |
| P(outcome) | Probability of achieving targeted clinical outcome |
| Persistence | Duration of effect (e.g., years) |
| Enterprise retention rate | Share of savings retained by the organization (e.g., ACO, health plan, full-risk entity) |
| Intervention cost | Total cost to deliver intervention, including care team, technology, and member support |
| Strategy | When to use | Illustrative examples |
|---|---|---|
| Build | Core capabilities, differentiating assets, long-term scale | Care management platform, in-house care teams |
| Buy | Proven solutions, faster time to value, non-core capabilities | Digital MSK program, behavioral health platform |
| Enable | Strengthen existing provider or community partners | PCP care management support, FQHC enablement |
| Refer | High-quality external programs, specialized clinical needs | Community-based organizations, condition-specific centers of excellence |
ACCESS turns chronic-care capacity into a priceable external intervention class; the finance question is return on the healthcare dollar, not technology novelty.
Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 07 / 10
AHEAD, hospital global budgets & social-care infrastructure
Aligning Hospital Payment Reform with Community Care to Drive a Healthier, More Resilient New York.
AHEAD & hospital economics
New York’s AHEAD model moves hospital economics from volume-based, fee-for-service toward prospective global budgets, with stronger integration with advanced primary care. This shift rewards better outcomes, population health, and total cost management — not higher volumes.
Today: activity-based hospital economics
- Fee-for-service payments
- Incentive to increase volume
- Fragmented care across settings
- Higher cost, variable outcomes
Align → Invest → Integrate → Measure → Improve
AHEAD: global budgets & advanced primary care
- Prospective global budgets
- Incentive for value and population health
- Stronger hospital–primary care integration
- Coordinated care across medical and social services
- Lower cost, better outcomes, more equitable care
A transformation of more than $5B
New York’s AHEAD-related transformation has been described as more than $5B in payment transformation across participating hospitals and payers.
Evidence from Maryland’s experience
- $1.6B — approximate Medicare savings from 2014–2022 under Maryland’s global budget model.
- 11 percentage points — lower hospital utilization than other states over 2013–2023, mainly through outpatient changes.
Incentive alignment across hospital and non-hospital care matters. Global budgets work best when paired with strong primary care, behavioral health, and social care investments.
NYHER & Social Care Networks
The NYHER waiver creates a statewide framework to invest in social-care infrastructure, connecting health plans, providers, and community organizations. With $7.5B in total waiver funding — including up to $500M for Social Care Networks through March 2027 — New York can build a more integrated, community-based system that addresses health-related social needs (HRSN) and improves both health outcomes and total cost of care.
NYHER social care operating model
- $7.5B — NYHER waiver package to strengthen health and social care infrastructure.
- Up to $500M — for Social Care Networks through March 2027.
People & Communities: Healthier Lives / Stronger Neighborhoods / Greater Equity.
| Institution | Role |
|---|---|
| Health plans | PMPM support, care management, value-based contracts |
| Providers | Clinical care, HRSN screening, closed-loop referrals |
| Community organizations | Social-care services, community outreach, trusted relationships |
| Social Care Networks | Fee-schedule HRSN services, capacity building, workforce support |
| Function | Operating contribution |
|---|---|
| Data sharing & connectivity | Common data, shared insights |
| Closed-loop referrals | Track, confirm, measure impact |
| Better outcomes, lower costs | Integrated medical and social care |
| PMPM & value based payments | Sustainable funding for social care |
CFO insight
Social care must be evaluated as medical-cost ROI and persistence, not as a parallel mission program.
Source cited in the original: CMS AHEAD Model; Maryland Total Cost of Care Model evaluations; NYHER 1115 waiver materials; public filings and peer-reviewed literature.
CHAPTER 08 / 10
Data liquidity, prior authorization & the financial value of reduced latency
Interoperability as Operating Infrastructure.
Executive perspective
Data liquidity — the ability to move trusted, normalized information across the healthcare ecosystem — is an operating infrastructure requirement for a more efficient, equitable, and resilient enterprise. When claims, clinical, prior authorization, attribution, risk signals and network intelligence are interoperable, organizations can detect needs earlier, reduce administrative friction, and deploy capital where it creates the greatest clinical and financial value. Interoperability is no longer an IT project; it is a core operating capability that converts data into action and measurable results.
| Input | Information |
|---|---|
| Claims data | Medical, pharmacy, eligibility and payments |
| Clinical data | EHR, lab, imaging, care plans and SDOH |
| Prior authorization data | Requests, decisions, turnaround times and rationale |
| Attribution | Member alignment and provider relationships |
| Risk signals | Predictive models, gaps in care and emerging risk |
| Network intelligence | Provider performance, capacity and cost |
Interoperability layer / Decision engine
Normalize → Analyze → Apply rules → Generate insight → Drive action.
| Output | Operating contribution |
|---|---|
| Earlier intervention | Identify and address needs sooner |
| Lower administrative cost | Automate and streamline workflows |
| Faster prior authorization | Real-time exchange and decisions |
| Better provider reconciliation | Aligned data and fewer discrepancies |
| Reduced duplication | Single source of truth across systems |
| Improved continuity | Complete, longitudinal member view |
| Better risk visibility | Actionable insight at population and member level |
CMS-0057-F: APIs for a more connected healthcare system
The CMS-0057-F Interoperability and Prior Authorization rule advances national standards for data exchange through three key APIs:
- Provider Access API — Member data access for authorized providers.
- Payer-to-Payer API — Data exchange when members change plans.
- Prior Authorization API — Electronic prior authorization exchange.
Key requirements broadly begin in 2027, with phased implementation and expanded data sets to follow.
| Return mechanism | Operating change |
|---|---|
| 01 / Lower unit administrative cost | Fewer manual processes, rework, and denials. |
| 02 / Reduced friction | Less effort for members, providers and staff. |
| 03 / Faster time-to-care | Shorter cycle times from need to approved care. |
| 04 / Better forecasting | Richer, more timely data improves planning and capital allocation. |
| 05 / Shorter time from signal to intervention | Convert insight into action before costs escalate. |
The financial value of less distance
Reducing the distance between signal and action creates measurable financial value.
Signal: Claim; Clinical Event; Risk Alert; Prior Auth Request; Network Change.
Shorter Distance / Lower Cost / Higher Value.
Action: Intervene; Authorize; Coordinate; Allocate Capital; Improve Outcomes.
- Fewer avoidable acute events
- Lower administrative expense
- Higher provider productivity
- Better member experience
- Stronger medical margin
Data liquidity turns speed into savings — and savings into a healthier tomorrow.
Source cited in the original: CMS-0057-F, CMS Interoperability and Prior Authorization Rule (2024), industry literature, and author analysis (2025–2026).
CHAPTER 09 / 10
Capital allocation, ROIC & tail-risk scenarios
Disciplined capital for durable value in a lower-cost, higher-quality New York | 2026–2030.
Own / Partner / Enable / Exit
- Own — Build and scale core capabilities that create durable advantage.
- Partner — Share risk and scale through strategic relationships.
- Enable — Provide capital, data and capabilities to accelerate ecosystem value.
- Exit — Divest or sunset non-core assets to redeploy capital.
| Domain | Own | Partner | Enable | Exit |
|---|---|---|---|---|
| Primary Care | Own high-value primary care platforms (employed or JV). | Co-develop community primary care with health systems and FQHCs. | Enable independent primary care through value-based incentives and data support. | Exit low-performing or non-strategic primary care assets. |
| Specialty Management | Own select high-need specialties (e.g., cardiology, oncology) where outcomes and cost can be integrated. | Partner with specialist groups and centers of excellence. | Enable specialty performance through analytics, referrals and value-based contracts. | Exit specialty lines without scale, differentiation or ROI potential. |
| Chronic-Care Programs | Own core care management capabilities for high-burden populations. | Partner with community-based organizations for population management. | Enable chronic-care programs with care management tools and predictive analytics. | Exit fragmented chronic-care programs that lack measurable impact. |
| Home-Based Care | Own home-based care in key markets (e.g., hospital-at-home, advanced primary care). | Partner with home health and post-acute providers. | Enable home-based care with technology, remote monitoring and logistics. | Exit home-based care in markets without scale or regulatory support. |
| Behavioral Health | Own integrated behavioral health delivery in core markets. | Partner with behavioral health specialists and digital platforms. | Enable behavioral health through digital access and integrated referral pathways. | Exit stand-alone behavioral health assets that cannot integrate. |
| Social Care | Own high-impact community programs where clinical and social ROI is proven. | Partner with social service organizations and municipal programs. | Enable social care with shared data, screening and closed-loop referrals. | Exit social care initiatives without clear outcomes or sustainability. |
| Data Infrastructure | Own core data platforms, analytics, and interoperability capabilities. | Partner with technology and cloud providers. | Enable data use across the ecosystem with FHIR-based platforms and shared analytics. | Exit legacy data systems and non-core technology. |
| Risk Protection | Own core risk management capabilities (actuarial, underwriting, stop-loss governance). | Partner with reinsurance carriers and risk pools. | Enable risk protection through captives, risk corridors and innovative financing. | Exit or contract out risk functions that do not create strategic advantage. |
Risk-adjusted return on healthcare capital
RARHC = After-Tax Retained Economic Value / (Required Capital + Incremental Operating Capital)
Risk-adjusted return on healthcare capital (RARHC) measures the after-tax economic value generated per dollar of capital at risk, including both required capital (e.g., regulatory, risk, and working capital) and incremental operating capital (e.g., growth investments).
Downside scenarios stress more than medical trend
The severe scenario pairs 9% annual medical trend with lower revenue yield and shared savings, higher acuity, and larger claim volatility.
Medical trend
Annual % · scale 0 to 10
Revenue yield / risk score
% versus base · scale -10 to 0
Quality economics (shared savings)
% versus base · scale -40 to 0
Utilization mix (higher acuity)
% versus base · scale 0 to 15
Large-case volatility (>$1M claims)
% versus base · scale 0 to 100
Each panel has its own labeled scale. “Not specified” preserves the source’s missing base values.
| Scenario | Medical Trend (Annual) | Revenue Yield / Risk Score | Quality Economics (Shared Savings) | Utilization Mix (Higher Acuity) | Large-Case Volatility (>$1M Claims) |
|---|---|---|---|---|---|
| Base | +4.0% | — | — | — | — |
| P75 (Downside) | +5.5% | (3%) | (10%) | +5% | +25% |
| P90 (Downside) | +7.0% | (6%) | (20%) | +10% | +50% |
| P95 (Severe) | +9.0% | (10%) | (35%) | +15% | +100% |
Note: Illustrative scenarios for planning purposes. Percentages reflect directional sensitivity versus base case.
Initiative portfolio: return vs. capital intensity
The original portfolio illustration compares expected return and relative capital intensity across Behavioral Health, Chronic-Care Programs, Primary Care (Integrated), Home-Based Care, Social Care, Data Infrastructure, and Risk Protection.
Behavioral Health is shown with the highest expected return, followed by Primary Care (Integrated), Chronic-Care Programs, Home-Based Care, Social Care, Data Infrastructure, and Risk Protection. Social Care appears at the lowest relative capital intensity; Risk Protection at the highest.
The portfolio graphic provides relative positions without exact point values or a bubble-size legend. This text describes its ordering without assigning numerical returns.
Key takeaway
The base case is not the strategy; the distribution of outcomes is the strategy.
Disciplined capital allocation, realistic downside planning, and a diversified portfolio of initiatives create a more resilient, equitable and valuable New York healthcare system.
Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
CHAPTER 10 / 10
Public-market lens, board scorecard & final executive lesson
Closing the loop from market signals to board oversight to enduring enterprise value.
01 / What public markets actually watch
Investors track a consistent set of indicators across leading health plans. Recent examples illustrate the signals that matter most — medical-cost trend, reserve development, cash conversion, leverage, and quality-driven revenue.
| Company | Indicator | Management implication |
|---|---|---|
| Elevance Health | 89.7% benefit expense ratio in Q2 2026. | Investors monitor medical-cost trend and benefit expense performance as a core indicator of underwriting discipline and pricing adequacy. |
| CVS Health | 87.4% Health Care Benefits MBR in Q2 2026. | Reported favorable prior-year reserve development, highlighting the importance of reserve adequacy and claims-trend management. |
| UnitedHealth Group | $11.1B operating cash flow in Q2 2026. | Equal to approximately 1.9x net income, underscoring cash conversion as a key measure of earnings quality and capital flexibility. |
| Humana | 2026 outlook pressured by Stars headwinds. | Highlights the impact of quality-driven revenue and regulatory program performance on financial outlook and investor sentiment. |
02 / Board-level scorecard
Boards should monitor a concise set of measures that link strategy, execution, and financial outcomes.
| # | Scorecard item | What to measure | Why it matters |
|---|---|---|---|
| 01 | Revenue quality | Share from risk-adjusted, value-based arrangements | More durable and predictable earnings |
| 02 | Risk-adjusted medical spread | Premium revenue vs. risk-adjusted medical cost | Core unit economics and pricing discipline |
| 03 | Medical-cost trend | PMPM trend by population and line of business | Early indicator of margin and capital needs |
| 04 | Quality revenue at risk | Stars, HEDIS and VBC performance | Protects revenue and market position |
| 05 | Intervention ROI | Cost per member, medical cost savings, ROI | Validates clinical and financial impact |
| 06 | Provider cohort contribution | Cost, quality and total cost of care by cohort | Informs network strategy and contracting |
| 07 | Network leakage | Out-of-network utilization and spend | Preserves medical-cost savings and value |
| 08 | Reserve development | Prior-year reserve releases (charges) | Signals pricing accuracy and claims discipline |
| 09 | Cash conversion | Operating cash flow vs. net income | Funds growth, investments and resilience |
| 10 | Capital adequacy | RBC, liquidity and access to capital | Supports strategic flexibility and downturn readiness |
| 11 | Return on healthcare capital | Risk-adjusted ROIC | Links clinical performance to enterprise value |
| 12 | Persistence of earnings | Multi-year growth and margin consistency | Indicates a durable competitive advantage |
03 / Executive lesson
In accountable care, capability is the scarce asset.
The enduring value of a healthcare enterprise is not created by volume, but by the capability to price risk, underwrite intervention, orchestrate access, convert lower medical cost into cash, and retain value at attractive risk-adjusted returns on required capital. Organizations that consistently align people, data, capital and execution around this capability will be more resilient today and create a healthier, more equitable and valuable tomorrow.
Source cited in the original: CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).
About this edition
Web edition of the article shared by Azis Dabas on LinkedIn. The ten original sections, financial frameworks, illustrative figures, and source attributions are presented as readable text and tables. The 2026–2030 label is the article’s planning horizon. Public-policy and company statements retain the context of the supplied article; its broad source references do not identify individual source documents.
Continue: the healthcare AI value realization ledger